Lymphedema: How do we diagnose and reduce the risk of this dreaded complication of breast cancer treatment?

Michael J. Bernas, Robert L. Askew, Jane M. Armer, Janice N. Cormier

Research output: Contribution to journalReview articlepeer-review

34 Scopus citations


Lymphedema is an under-recognized, progressive, life-long condition estimated to impact 2-3 million people in the United States. The incidence of breast cancer related lymphedema varies greatly in the literature largely due to different measurement techniques, competing thresholds for defining lymphedema, and variation in length of follow-up. Multiple imaging techniques have become useful for diagnosis. Lymphoscintigraphy is one of the most commonly used, as it can identify pathways of lymphatic drainage, quantify extent of dermal backflow, and help determine functional and morphologic changes in the lymphatic system. Early detection and intervention hold the greatest promise of reducing the incidence of lymphedema. Health care providers involved with cancer patients need to become more educated about lymphedema, aware of current risk-reduction practices, and familiar with methods of diagnosis and assessment, so that patients with early swelling can be referred to lymphedema treatment specialists at a time when treatment is more effective.

Original languageEnglish (US)
Pages (from-to)53-58
Number of pages6
JournalCurrent Breast Cancer Reports
Issue number1
StatePublished - Mar 2010


  • Breast cancer
  • Lymphedema

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Lymphedema: How do we diagnose and reduce the risk of this dreaded complication of breast cancer treatment?'. Together they form a unique fingerprint.

Cite this